NCM
NKTR icon

Nearwater Capital Markets’s Nektar Therapeutics NKTR Stock Holding History

Nearwater Capital Markets’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.8M Buy
261,500
+200,000
+325% +$11.4M 0.44% 57
2025
Q4 		$2.6M Buy
+61,500
New +$3.44M 0.04% 99

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nearwater Capital Markets's NKTR Position: Q1 2026 in Review

Nearwater Capital Markets increased its Nektar Therapeutics (NKTR) stake by 325% in Q1 2026, buying an estimated $11.4M and bringing the position to 261,500 shares worth $18.8M. The position accounts for 0.44% of the portfolio, ranked #57.

Nearwater Capital Markets first reported a position in NKTR in Q4 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Nearwater Capital Markets held 261,500 shares of Nektar Therapeutics worth $18.8M as of Q1 2026.
  • Nearwater Capital Markets bought 200,000 Nektar Therapeutics shares in Q1 2026, an estimated $11.4M.
  • Nektar Therapeutics made up 0.44% of Nearwater Capital Markets's portfolio in Q1 2026, its #57 holding.
  • Nearwater Capital Markets first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Nearwater Capital Markets's 13F filing for Q1 2026, filed 15 May 2026.